We present an unusual case of a 37-year old male who presented with a three-week history of diplopia, vertigo, left facial numbness, and left facial droop. MRI demonstrated a contrast enhancing mass at the left pontomedullary junction and extending into the cerebellum. Biopsy was consistent with crystal-storing histiocytosis, which is characterized by abnormal cytoplasmic aggregation of immunoglobulin crystals in histiocytes. To our knowledge, this is the first case of crystal-storing histiocytosis described in the brainstem and cerebellum and one of only a handful described in the central nervous system. This rare disorder is usually associated with underlying lymphoplasmacytic disorders or less commonly inflammatory or infectious disease. However, none of these have been identified thus far in this case. The patient received a short oral steroid course with resultant radiologic normalization. We review the crystal-storing histiocytosis literature and propose continued regular surveillance for the development of lymphoplasmacytic disease. BACKGROUND: Methylation of the O6-methylguanine-DNA methyltransferase (MGMT) gene promoter is an important consideration for treatment decision-making in glioblastoma; it portends a better prognosis and predicts efficacy of temozolomide chemotherapy. MGMT promoter methylation status is especially valuable for treatment decision-making in elderly patients or when enrolling in certain clinical trials. Optimizing the delivery of this and other molecular information is critical to provide the best care for glioblastoma patients. We previously reported improved turnaround-time (TAT) with process interventions and now aim to present longterm follow up data, as well as preliminary results using a novel laboratory technique. METHODS: Using the electronic medical record and pathology tracking system, we performed process mapping and multidisciplinary process intervention planning. We then modified the MGMT promoter methylation testing procedure to use ethanol-fixed specimens directly from the frozen pathology laboratory. RESULTS: Baseline average TAT from tumor resection to MGMT methylation result was 23.4 days (SD 5.6) during the two years (139 cases) prior to intervention, including 5 days (SD 2.6) from resection to neuropathological diagnosis, and 17.5 days (SD 4.1) from neuropathological diagnosis to MGMT result. After two process interventions and one year of follow up, the average TAT is 17.2 days (SD 5) (p<0.0001). Sixteen cases were tested using our novel fresh tissue method, and average TAT was 11.4 days (SD 6.4) (p<0.0001), a 51% reduction from baseline. Further, 50% of these cases were resulted prior to initial post-operative neuro-oncology consultation, compared to 10% during the baseline period (p=0.0107). CONCLUSION: While process intervention led to significant TAT reduction for MGMT methylation status, our novel technique resulted in marked additional improvement. Further, neuro-oncology consultations were molecularly-informed significantly more often. Machine failure led to delayed results in several cases, and we expect even better outcomes moving forward. Additional development of this novel technique is warranted.
BACKGROUND: Methylation of the O6-methylguanine-DNA methyltransferase (MGMT) gene promoter is an important consideration for treatment decision-making in glioblastoma; it portends a better prognosis and predicts efficacy of temozolomide chemotherapy. MGMT promoter methylation status is especially valuable for treatment decision-making in elderly patients or when enrolling in certain clinical trials. Optimizing the delivery of this and other molecular information is critical to provide the best care for glioblastoma patients. We previously reported improved turnaround-time (TAT) with process interventions and now aim to present longterm follow up data, as well as preliminary results using a novel laboratory technique. METHODS: Using the electronic medical record and pathology tracking system, we performed process mapping and multidisciplinary process intervention planning. We then modified the MGMT promoter methylation testing procedure to use ethanol-fixed specimens directly from the frozen pathology laboratory. RESULTS: Baseline average TAT from tumor resection to MGMT methylation result was 23.4 days (SD 5.6) during the two years (139 cases) prior to intervention, including 5 days (SD 2.6) from resection to neuropathological diagnosis, and 17.5 days (SD 4.1) from neuropathological diagnosis to MGMT result. After two process interventions and one year of follow up, the average TAT is 17.2 days (SD 5) (p<0.0001). Sixteen cases were tested using our novel fresh tissue method, and average TAT was 11.4 days (SD 6.4) (p<0.0001), a 51% reduction from baseline. Further, 50% of these cases were resulted prior to initial post-operative neuro-oncology consultation, compared to 10% during the baseline period (p=0.0107). CONCLUSION: While process intervention led to significant TAT reduction for MGMT methylation status, our novel technique resulted in marked additional improvement. Further, neuro-oncology consultations were molecularly-informed significantly more often. Machine failure led to delayed results in several cases, and we expect even better outcomes moving forward. Additional development of this novel technique is warranted. In order to resect brain tumors while preserving the patient's brain functions, neurosurgeons apply intraoperative direct cortical stimulation (DCS) during awake surgery. Apart from language mapping, some highly specialized centers also map further higher cortical functions such as calculation function. Recently, the feasibility of mapping calculation function by repetitive navigated transcranial magnetic stimulation (rTMS) in healthy volunteers has been shown. OBJECTIVE: To correlate the resection of calculation-positive sites in terms of rTMS with functional patient outcome of calculation performance. METHODS: Nine patients with right-or left-sided (7 right-, 2 left-sided) parietal brain tumors (7 gliomas, 2 metastases) underwent preoperative rTMS calculation mapping. We stimulated 52 previously determined cortical sites over the whole tumor hemisphere while patients performed a calculation task with 80 simple arithmetic operations. Pre-and postoperatively, patients performed a standardized number processing and calculation test (NPCT). RESULTS: The overall error rate (ER = calculation errors per stimulations) for tumor hemispheres was 7.3%. The resection of calculation-positive sites in terms of rTMS worsened the postoperative NPCT result in 6 cases. In 2 cases no calculation-positive sites were resected and the postoperative NPCT result was similar or better than preoperatively. In one case the postoperative NPCT result was better than preoperatively although calculation-positive sites were resected. According to these results sensitivity and negative predictive value are 100%, specificity is 66.7%, and positive predictive value is 85.7%. CONCLUSION: The resection of calculation-positive sites in terms of rTMS correlated with postoperative NPCT results in 8 of 9 cases. Despite only presenting a low number of cases, rTMS might be a useful tool for preoperative mapping of calculation function. However, the reliability of the present results has to be evaluated in a larger series.
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